Yeungnam Univ J Med Search

CLOSE


Yeungnam Univ J Med > Volume 31(2); 2014 > Article
Yeungnam University Journal of Medicine 2014;31(2):82-88.
DOI: https://doi.org/10.12701/yujm.2014.31.2.82    Published online December 31, 2014.
Weekly irinotecan and carboplatin for patients with small cell lung cancer.
Hye Won Lee, Eu Gene Jeong, Dong Hyun Kim, Hyuk Lee, Bo Hyoung Kang, Soo Jung Um, Meesook Roh, Choonhee Son
1Division of Respiratory Medicine, Department of Internal Medicine, Dong-A University College of Medicine, Dong-A University Medical Center, Busan, Korea. sjum@dau.ac.kr
2Department of Pathology, Dong-A University College of Medicine, Dong-A University Medical Center, Busan, Korea.
Abstract
BACKGROUND: Lung cancer is the most common cause of cancer-related death worldwide and in Korea, and small cell lung cancer (SCLC) is the most deadly tumor type in the different lung cancer histology. Chemotherapy is the main strategy of the treatment for SCLC, and etoposide and platinum regimen has been the only standard chemotherapy for about 30 years. To test feasibility of weekly divided dose irinotecan and carboplatin for Korean patients is the aim of this study. METHODS: Patients with histologically or cytologically confirmed extensive stage SCLC were included. Patients with limited stage (LD), who could not tolerate concurrent chemoradiotherapy were also included. All the patients received irinotecan 60 mg/m2, carboplatin 2 area under the curve at day 1, 8, and 15 every 4 weeks. Study regimen was discontinued when the disease progressed or intolerable side effects occurred. No more than 6 cycles of chemotherapy were given. RESULTS: Total 47 patients were enrolled, among them 9 patients were LD. Overall response rate was 74.5% (complete response, 14.9%; partial response, 59.6%). Side effects greater than grade 3 were neutropenia (25.5%), fatigue (12.8%), thrombocytopenia (8.5%), sepsis (4.3%), and pancytopenia (2.1%). There was no treatment related death. CONCLUSION: Weekly divided irinotecan and carboplatin regimen is effective, and safe as a first line therapy for both stage of SCLC. Large scaled, controlled study is feasible.
Key Words: Cisplatin, Irinotecan, Small cell lung carcinoma


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
AUTHOR INFORMATION
Editorial Office
170 Hyeonchung-ro, Nam-gu, Daegu 42415, Korea
Tel: +82-53-640-6832    Fax: +82-53-651-0394    E-mail: yujm@yu.ac.kr                

Copyright © 2019 by Yeungnam University College of Medicine. All rights reserved.

Developed in M2community

Close layer
prev next